CBIO CRESCENT BIOPHARMA
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 12 analyst firms say about CRESCENT BIOPHARMA: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
10 rated views · 12 analyst/firm records · 12 firms
Radar score
- Russell 2000 · Top Picks · 6MGood · #64 in the index84
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8057
Recent analyst activity · last 90 days
Our tracked history has 6 reports on CBIO from 4 analyst firms in the last 90 days (12 firms in the past year).
Comparing each firm's latest target with its previous one: 2 left it unchanged and 1 has its first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: HC Wainwright raised its target from $22.00 (set 2 Mar 2026) to $36.00 on 6 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Cantor Fitzgerald | Eric Schmidt | Buy | 15 Jun 2026 | — |
| Guggenheim | Bradley P Canino | Buy | 30 Apr 2026 | 35.00 USD |
| H.C. Wainwright | Mitchell S. Kapoor | Buy | 19 Oct 2026 | 36.00 USD |
| Jefferies | Akash Tewari | Buy | 1 Jul 2026 | 35.00 USD |
| Lifesci Capital | Charles Zhu | Buy | 30 Apr 2026 | 28.00 USD |
| Piper Sandler | Biren Amin | Buy | 30 Jul 2026 | 35.00 USD |
| Stifel | Stephen Willey | — | 26 Feb 2026 | 29.00 USD |
| TD Cowen | Tyler Van Buren | Buy | 24 Aug 2026 | — |
| UBS | Unnamed analyst | Buy | 19 Oct 2026 | 36.00 USD |
| Wedbush | Robert Driscoll | Buy | 14 Sep 2026 | 27.00 USD |
| Weiss Ratings | Unnamed analyst | — | 7 Aug 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 07:01 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.